Viking Therapeutics: Best GLP-1 Stock

This is a the United States news story, published by Yahoo Finance (Canada), that relates primarily to Morgan Stanley news.

the United States news

For more the United States news, you can click here:

more the United States news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance (Canada) news

For more news from Yahoo Finance (Canada), you can click here:

more news from Yahoo Finance (Canada)

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

global obesity drugs market

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest obesity drugs news, obesity medications news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

obesity drugs market

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Is Viking Therapeutics, Inc. (VKTX) a Good Addition to Your Portfolio Right Now?

Summary

Nutrition label

81% Informative

More than one billion people worldwide are obese , including 650 million adults, 340 million adolescents, and 39 million children.

A brand-new class of weight-loss drugs that don't require diets or intense exercise appears to be revolutionary.

Global obesity drugs market will reach $105 billion in 2030 , up from a previous estimate of $77 billion .

In 2023 , branded obesity drugs generated $6 billion in sales.

1.5 million out of the 110 million eligible patients in the United States are currently undergoing treatment with GLP-1 drugs.

The obesity drugs market is a high-growth industry and since it's in its early innings, now may be a time to add some weight loss stocks to your watchlists.

Morgan Stanley projects the weight-loss medicine market to reach $105 billion by 2030 .

Disclosure: None. This article is originally published at Insider Monkey ..

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive